Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 8/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242193 | 0.87 | GSK3A (0.41) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL3031556 | 0.84 | GSK3A (0.39) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL13221083 | 0.79 | GSK3B (0.53) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL3028207 | 0.79 | GSK3B (0.55) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL5311550 | 0.78 | KDM4E (0.41) | GSK3BGSK3AALDH1A1TSHRMAPK1 | |
| SCHEMBL13221325 | 0.78 | GSK3B (0.54) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL5317535 | 0.76 | BPTF (0.46) | ITKL3MBTL1ALDH1A1TSHRMAPK1 | |
| SCHEMBL13220943 | 0.75 | IGF1R (0.45) | GSK3BGSK3AITKAURKAAURKB | |
| SCHEMBL5318263 | 0.75 | MAPT (0.41) | ALDH1A1TSHRMAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL801702 | 0.74 | GSK3B (0.65) | GSK3BGSK3AITKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | GSK3B 200/4885GSK3A 217/4885ITK 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.